Myia Health

Babyscripts is a doctor-delivered, digital health tool for prenatal care, enhancing the doctor/patient relationship outside of the clinic's walls during routine, low-risk pregnancy care and providing remote monitoring to better identify high-risk pregnancies.

Sensome develops micro-sensor technology for smart medical devices. Sensome's sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body and machine learning algorithms for accurate and predictive real-time analysis.

TytoCare connects people to clinicians to provide virtual home examinations and diagnosis solutions. TytoCare's solutions are designed to enable a comprehensive medical exam with clinicians, from any location.

Glooko's universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. Glooko's systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake.

EarlySense provides contact-free, continuous monitoring solutions for the medical and consumer digital health markets. EarlySense's patented sensor and advanced algorithms monitor and analyze cardiac, respiratory, sleep and motion parameters. Used in hospitals and healthcare facilities worldwide, EarlySense assists clinicians in early detection of patient deterioration, helping to prevent adverse events, including code blues, preventable ICU transfers, patient falls and pressure ulcers. Additionally, the company's myEarlySense smart home-compatible consumer solution brings hospital-proven technology to the home, providing valuable data regarding wellness and sleep.

Element Science focuses on solutions at the intersection of life-saving therapies, wearable devices, and patient-centric design. The company develops a cost-effective wearable therapeutic device that aims to re-define the treatment for temporary periods of elevated sudden cardiac death risk.